Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01959672
Recruitment Status : Recruiting
First Posted : October 10, 2013
Last Update Posted : March 3, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Chi Lin, MD, University of Nebraska

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2018
  Study Completion Date : No date given